ODDO BHF

GAINS Associates Strengthens Ecosystem with Strategic Addition of Three Industry-Leading Advisors

Retrieved on: 
星期一, 五月 27, 2024

Dubai, UAE, May 27, 2024 (GLOBE NEWSWIRE) -- GAINS Associates, a pioneer in decentralized venture capital, is thrilled to announce the strategic addition of three new advisors to its robust ecosystem.

Key Points: 
  • Dubai, UAE, May 27, 2024 (GLOBE NEWSWIRE) -- GAINS Associates, a pioneer in decentralized venture capital, is thrilled to announce the strategic addition of three new advisors to its robust ecosystem.
  • The new advisors, Walid Benothman, Evan Luthra, and Jonathan Faye, bring a wealth of experience and expertise that will undoubtedly fortify GAINS Associates' market position and help spearhead innovative developments.
  • His entrepreneurial spirit and extensive network will significantly enhance GAINS Associates' visibility and strategic planning.
  • The integration of these three advisors is set to bring a fresh perspective and drive significant advancements in GAINS Associates’ operational strategies.

Sword Group: H2 2023 Report of the Liquidity Agreement

Retrieved on: 
星期四, 三月 28, 2024

Under the liquidity contract awarded by Sword Group to ODDO BHF, as of 31/12/2023, the following resources appeared on the account of liquidity:

Key Points: 
  • Under the liquidity contract awarded by Sword Group to ODDO BHF, as of 31/12/2023, the following resources appeared on the account of liquidity:
    - Number of transactions executed during the semester at purchase: 1,116
    - Number of transactions executed during the semester on sale: 1,080
    - Volume exchanged over the semester upon purchase: 34,943 shares for an amount of €1,319,183
    - Volume exchanged over the semester for sale: 38,733 shares for an amount of €1,455,889
    As a reminder, during the last balance sheet of 30/06/2023, the following resources appeared in the liquidity account:
    The implementation of the liquidity contract is carried out in accordance with AMF Decision No.
  • 2018-01 dated July 2, 2018, establishing liquidity contracts on equity securities as accepted market practice.

Commerzbank increases net profit for 2023 to €2.2 billion – Strategy is delivering

Retrieved on: 
星期四, 二月 15, 2024

On this basis, we will achieve a further increase in net profit for the current year”, said CEO Manfred Knof.

Key Points: 
  • On this basis, we will achieve a further increase in net profit for the current year”, said CEO Manfred Knof.
  • Net interest income rose by a third to €8.368 billion (2022: €6.459 billion), while net commission income was slightly down at €3.386 billion (2022: €3.519 billion).
  • Net profit also rose accordingly: compared to the previous year, net profit after taxes and minority interests increased by 55% to €2.224 billion (2022: €1.435 billion).
  • Revenues amounted to €1.106 billion (Q3 2023: €1.171 billion); the operating result totalled €508 million (Q3 2023: €644 million).

EQS-News: Commerzbank increases net profit for 2023 to €2.2 billion – Strategy is delivering

Retrieved on: 
星期四, 二月 15, 2024

On this basis, we will achieve a further increase in net profit for the current year”, said CEO Manfred Knof.

Key Points: 
  • On this basis, we will achieve a further increase in net profit for the current year”, said CEO Manfred Knof.
  • Net interest income rose by a third to €8.368 billion (2022: €6.459 billion), while net commission income was slightly down at €3.386 billion (2022: €3.519 billion).
  • Net profit also rose accordingly: compared to the previous year, net profit after taxes and minority interests increased by 55% to €2.224 billion (2022: €1.435 billion).
  • Revenues amounted to €1.106 billion (Q3 2023: €1.171 billion); the operating result totalled €508 million (Q3 2023: €644 million).

EQS-News: RENK Group AG and Triton decided for final private placement volume of RENK Group AG shares

Retrieved on: 
星期二, 二月 6, 2024

to institutional investors in an accelerated bookbuilding process

Key Points: 
  • to institutional investors in an accelerated bookbuilding process
    The final offer will include 33,333,333 shares held by the selling shareholder Rebecca BidCo S.à r.l.
  • RENK Group AG shares are expected to be traded on the regulated market of the Frankfurt Stock Exchange (Prime Standard) starting February 7, 2024, under the Ticker Symbol R3NK.
  • Following the listing, Triton will continue to hold the majority of the shares of RENK Group AG.
  • The expected free float amounts to 27% (excluding around 6.67 million shares purchased by KNDS N.V. as cornerstone investor), creating a liquid market for shares of the RENK Group AG.

EQS-News: RENK Group AG and Triton initiate private placement

Retrieved on: 
星期一, 二月 5, 2024

NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL

Key Points: 
  • NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL
    RENK Group AG and Triton initiate private placement of RENK Group AG shares and aim for listing on February 7, 2024
    Private placement of RENK Group AG shares held by the selling shareholder Rebecca BidCo S.à r.l.
  • Following the listing, Triton will continue to hold the majority of the shares of RENK Group AG.
  • Assuming full exercise of the greenshoe option, free float amounts to up to 30%, creating a liquid market for shares of the RENK Group AG.
  • The investment of KNDS into the RENK Group AG will further support the strategic international growth of RENK, strengthening its market position.

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Retrieved on: 
星期二, 一月 16, 2024

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with NATIXIS ODDO BHF.

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with NATIXIS ODDO BHF.
  • Under the liquidity contract between DBV Technologies and NATIXIS ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2023:
    When the liquidity contract with ODDO BHF was implemented, as of July 1, 2018, the following assets were included in the liquidity account:
    Over the period from July 1, 2023, to December 31, 2023, the following transactions were executed:
    376,978 shares and € 911,734.76 on purchases,
    303,962 shares and € 744,017.58 on sales.

Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum

Retrieved on: 
星期四, 一月 4, 2024

Saint-Herblain (France), January 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that members of its management team including Thomas Lingelbach, CEO and Peter Bühler, CFO will hold investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference, January 8 – 10, 2024 in San Francisco and virtually at the Oddo BHF Forum on January 15,2024.

Key Points: 
  • Saint-Herblain (France), January 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that members of its management team including Thomas Lingelbach, CEO and Peter Bühler, CFO will hold investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference, January 8 – 10, 2024 in San Francisco and virtually at the Oddo BHF Forum on January 15,2024.
  • Valneva’s CEO and CFO will notably discuss the Company’s advanced vaccine development pipeline, including its Lyme disease vaccine candidate VLA15 (Phase 3 fully enrolled, partnered with Pfizer), as well as the Company’s growing commercial business, which now includes recently FDA-approved1 IXCHIQ®, the world’s first licensed vaccine for prevention of disease caused by chikungunya virus, launching in early 2024.
  • To schedule a 1on1 investor meeting with Valneva, institutional investors and analysts can

Crossject announces initiation of coverage by ODDO BHF

Retrieved on: 
星期二, 十一月 28, 2023

Dijon, France November 28, 2023, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, announces initiation of coverage of its stock by analysts at independent financial group ODDO BHF.

Key Points: 
  • Dijon, France November 28, 2023, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, announces initiation of coverage of its stock by analysts at independent financial group ODDO BHF.
  • All reports on Crossject prepared by analysts represent the views of those analysts, and are not necessarily those of Crossject.
  • ODDO BHF SCA and the issuer have agreed that ODDO BHF SCA will produce and disseminate investment recommendations on the issuer equity side as a service to the issuer.
  • This Research Report is for the use of eligible counterparties and professional clients of ODDO BHF SCA only.

Appointments within SCOR Investment Partners

Retrieved on: 
星期五, 十一月 24, 2023

Louis Bourrousse is appointed Chief Executive Officer of SCOR Investment Partners.

Key Points: 
  • Louis Bourrousse is appointed Chief Executive Officer of SCOR Investment Partners.
  • Under Louis Bourrousse’s leadership, SCOR Investment Partners’ executive committee brings together: Benjamin Ayache (Chief Operating Officer), Alexandre Jaeglé (Head of Business Development), Thibaut Lameyse (General Secretary), Marie-Suzanne Mazelier (Chief Investment Officer and Deputy Chief Executive Officer) and Eric Talleux (Chief Risk Officer and Deputy Chief Executive Officer).
  • François de Varenne, Group Chief Financial Officer and Deputy Chief Executive Officer of SCOR, comments: “These appointments, all internal promotions, bear witness to the deep talent pool we have assembled at SCOR Investment Partners.
  • Prior to joining SCOR Investment Partners, he spent five years at Groupama Asset Management.